Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

JOHNSON & JOHNSON Director's Dealing 2017

Mar 7, 2017

29750_dirs_2017-03-07_b359852f-3ec8-4657-a53e-b0ddc97e8a86.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: JOHNSON & JOHNSON (JNJ)
CIK: 0000200406
Period of Report: 2017-03-03

Reporting Person: Duato Joaquin (Exec VP, WW Chair, Pharma)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-03-03 Common Stock M 29158.0000 $58.3300 Acquired 97694.0000 Direct
2017-03-03 Common Stock M 20842.0000 $61.7500 Acquired 118536.0000 Direct
2017-03-03 Common Stock S 50000.0000 $123.6228 Disposed 68536.0000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-03-03 Employee Stock Options (Right to Buy) $58.3300 M 29158.0000 Disposed 2019-02-08 Common Stock (29158.0000) Direct
2017-03-03 Employee Stock Options (Right to Buy) $61.7500 M 20842.0000 Disposed 2018-02-10 Common Stock (20842.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 570.0000 Indirect

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $123.35 to $123.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (2/28/2017).